Protein C (PC) is considered to be an important regulator of blood coagulation and fibrinolysis. During the production of monoclonal antibodies (MoAbs) against human PC in mouse ascitic fluid, one hybridoma was found to induce heavy thrombus in mice, resulting in severe hemorrhage. Intravenous infusion of the purified MoAb (PCO1) from this hybridoma also caused thrombosis in mice. The crossreacting substance was then isolated from mouse plasma with ROTEIN C (PC) is a vitamin K-dependent serine P protease that regulates blood coagulation by inactivation of factor Va and factor VIIIa.'" PC also has profibrinolytic activity by inactivation of plasminogen activator i n h i b i t~r .~.~ In either the intrinsic or extrinsic coagulation cascade, the final trigger enzyme is thrombin, which cleaves fibrinogen to fibrin. Thrombin also binds to thrombomodulin on the endothelial cell surface of blood vessel, and the resulting complex has no more affinity to fibrinogen, but exclusively catalyzes PC activation. 6 In this drastic change of the direction from coagulation to anti-coagulation, PC plays an important role, which is probably processed locally. To understand the dynamic aspect of the regulation of thrombosis, a convenient in vivo assay system is needed.
Accumulated evidence indicates a critical role of P C in blood coagulation in animal experiment^.'.^ Kumada et all0 have shown that thrombomodulin protected the lethal thromboembolism induced by thrombin in mice, suggesting an anti-coagulant role of activated PC. Taylor et all' also have demonstrated that a monoclonal antibody (MoAb) against PC that blocked the activation of PC potentiated the lethal effects of Escherichia coli in baboons. Inhibition of blood clotting by the infusion of activated PC in baboons has been shown by Gruber et a1.I'
In this study we demonstrate that anti-PC MoAb potentiates thromboembolism in mice, and we describe mouse PC isolated by this antibody.
PCOl immunoaffinity column, which was identified as mouse PC by several criteria. Mouse PC prolonged the activated partial thromboplastin time of mouse plasma, and PCOl neutralized this in vitro anti-coagulant activity. Therefore, heavy thrombosis observed in PCOl -treated mice is likely to be ascribed to the defect of PC caused by PCOl . 0 1990 by The Americen Society O f Hem8tOlOgy.
antin, and thymidin from Wako (Osaka, Japan); aminopterin from Sigma; fetal calf serum (FCS) from GIBCO.
PC activator was purified from the lyophilized venom of Agkistrodon contortrix contortrix (Sigma) according to the method described."
Preparation of MoAbs. Mice (BALB/c) were immunized with 50 pg of purified human PC subcutaneously and intraperitoneally with complete Freund's adjuvant (DIFCO). Mice were boosted twice with 30 pg of PC with incomplete Freund's adjuvant (DIFCO) at 2-week intervals. Spleen cells from immunized mice were hybridized with mouse myeloma, P3-X63-Ag8-U1 (P3U1), by the standard pr~cedure.'~ Anti-human PC MoAbs were screened by antigencoated enzyme-linked immunosorbent assay (ELISA). Briefly, microtiter plate (Sanko Junyaku, Japan) for ELISA was coated with 5 pg/mL of human PC for 1 hour, and blocked with 1% gelatine in TBST (50 mmol/L Tris-HC1, pH 7.2, 0.15 mol/L NaC1, 0.01% Tween 20). Culture sup (50 pL) was added to the microtiter wells to incubate for 1 hour. Then 50 pL of peroxidase-labeled rabbit anti-mouse immunoglobins (Igs) (DAKO, Denmark) was added after washing wells with TBST. Peroxidase activity was measured by adding substrate solution (1 mg/mL o-phenylenediamine, 0.006% H,O, in 0.1 mol/L Na-citrate buffer, pH 5.0). Reaction was stopped by the addition of 50 pL of 2 mol/L H,S04 and absorbance at 490 nm was measured by ELISA Auto reader (Dynatech). All steps were performed at room temperature. For the screening of calciumdependent antibodies, 5 mmol/L CaCI, was added throughout the steps before peroxidase reaction.
All MoAbs were purified by protein A Sepharose (Pharmacia, Sweden).
Competitive radioimmunoassay. PC was iodinated with carrierfree Na"'I (Amersham, England) by the IODO-GEN (Pierce) according to the manufacturer's instructions. Polyvinyl microplate was coated with 5 pg/mL of purified antibody for 1 hour and blocked with 1% gelatin in TBST. Increasing amounts of competitors were added with I2'I-labeled PC (37 MBq/10 pg) in TBST containing 5 mmol/L CaC1,. After 1 hour of incubation, wells were washed with the same buffer and bound radioactivity was measured by a gamma counter (Aloka, Tokyo, Japan).
Anti-coagulant activity of PC in plasma was measured by activated partial thromboplastin time (APTT).'' Briefly, 50 pL of human plasma and 50 pL of TBS (50 mmol/L Tris HC1, pH 7.2, 0.15 mol/L NaCI) were incubated with 50 pL of PC activator (1 U/mL) for 5 minutes at 37OC. Then 50 pL of Pathromtin (Behringwerke, West Germany) was added. After incubation for 1 minute, 50 pL of 25 mmol/L CaCI, was added, and then clotting time was measured. Mouse plasma was incubated in the same manner with PC activator for 1 minute at 37"C, and then Pathromtin was added. After incubation for 19 minutes, CaCI, was added and clotting time was measured.
Amidolytic activity of activated PC was measured with the substrate of H-D-Lys-Z-Pro-Arg-pNA (chromozym PCa, Boehringer Mannheim) in 50 mmol/L Tris-HC1, pH 8.0, 0.1 mol/L NaC1. After incubation for 5 minutes at 37OC. reaction was PC assay in plasma. terminated by adding 50% acetic acid, and absorbance at 405 nm was measured by spectrophotometer (Shimazu, Tokyo, Japan).
One milliliter of 50 mmol/L phenylmethylsulfonyl fluoride was added to 50 mL of mouse plasma and stirred for 1 hour with 4 mL of 1 mol/L BaCI,. The precipitate was collected by centrifugation and washed twice with 0.1 mol/L NaCl containing 1 mmol/L benzamidine-HC1 and 0.02% NaN,. The washed barium citrate precipitate was suspended in 40% saturated ammonium sulfate solution containing 5 mmol/L EDTA and 50 mmol/L Tris-HC1, pH 7.2. Diisopropyl fluorophosphate (1 mmol/ L) was added and the suspension was stirred for 2 hours. Precipitate Preparation of mouse PC. was eliminated by centrifugation and the supernatant was dialyzed against TBS. The dialyzate was made in 5 mmol/L CaCl,, and applied to PCOl conjugated CH-sepharose affinity column (10 mg of PCO1/2 mL of gel). After washing the column with TBS containing 5 mmol/L CaCI,, mouse PC was eluted with TBS containing 5 mmol/L EDTA. The peak fractions were pooled and dialyzed against 20 mmol/L Tris-HCI, pH 8.0,O.l mol/L NaCI, and applied to Q-sepharose column (1.2 mL) which was previously equilibrated with 20 mmol/L Tris HCI, pH 8.0.0.1 mol/L NaCl. After washing of the column with the same buffer, linear salt gradient elution was performed from 0.1 to 0.5 mol/L NaCl in equilibration buffer (40 mL). All the procedures were performed at 4OC.
First, 40 pL of mouse PC and 40 pL of TBS were incubated with 20 pL of PC activator (10 U/mL) for 20 minutes at 37OC, and the activation was terminated by adding 100 pL of 25 mmol/L CaCI,. Amidolytic activity of activated PC was measured with the substrate of H-D-Lys-Z-Pro-Arg-pNA (chromozym PCa, Boehringer Mannheim) in 50 mmol/L Tris-HCI, pH 8.0, 0.1 mol/L NaCI. After incubation for 5 minutes at 37OC, reaction was terminated by adding 50% acetic acid, and absorbance at 405 nm was measured by spectrophotometer (Shimazu). Anticoagulant activity of purified mouse PC was measured using mouse plasma. Fifty microliters of mouse plasma was incubated with 50 pL of TBS for 1 minute at 37OC. Then 50 pL of Pathromtin was added. After incubation for 1 minute, 100 p L of activated mouse PC containing CaCI, was added, and following clotting time was measured.
Immunoblotting. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis, (SDS-PAGE), 12.5%, was performed,I6 and proteins were electro-transferred to vinylidene fluoride membrane (Atto, Tokyo, Japan). Strips cut from the membrane were incubated with respective antibodies (10 pg/mL). After washing, antigen bands were visualized by the incubation with peroxidase-labeled rabbit anti-mouse Ips antibody and Konica Immunostaining HRP Kit IS-SOB (Konica, Tokyo, Japan).
Assay of purified mouse PC.

RESULTS
Specificity of MoAbs. Purified PCOl bound human PC
in the calcium-dependent manner that required nearly 1 mmol/L calcium ion (Fig 1) . T h e cross-reactivity of PCOl with other vitamin K-dependent coagulation factors was For personal use only. on September 24, 2017. by guest www.bloodjournal.org From surroundings were accompanied with hemorrhage. Neither thrombus nor hemorrhage was detected in PC02 hybridomainjected mice. Thrombus was positive in both periodic acid Shiff (PAS) reaction and phosphotungstic acid hematoxylin (PTAH) staining, indicating that the fibrinous clot was formed. Neutrophil infiltration and nectosis were observed around the eyeball and lacrimal gland (Fig 3, A and B) . In kidney (Fig 3C) and lung, hyaline thrombus was observed.
Thus. the hemorrhage observed was not due to the simple hyper fibrinolysis but rather theconsequenceofa hyperthrombotic state. The symptom was rather systemic and looked like disseminated intravascular coagulation (DIC).
To identify the crossreacting substance with PCOl antibody in mouse plasma, pooled mouse plasma was condensed by barium precipitation and subjected to immunoblotting analysis (Fig 4A) finity column as described in Experimental Procedures. SDS-PAGE of purified mouse PC showed a major band of 64 Kd under nonreduced condition, and a heavy chain of 41 Kd and a light chain of 21 Kd (nearly at 1:l molar ratio) under reduced condition, which was consistent with the result of immunoblotting (Fig 4B) . Function of purified mouse PC was examined by in vitro assay system. PC activator prepared from Agkistrodon contortrix contortrix activated mouse PC, very slowly compared with human PC. Activated mouse PC hydrolyzed the synthetic substrate of H-D-Lys-ZPro-Arg-pNA (chromozym PCa, Boehringer Mannheim), which was not inhibited by antithrombin I11 (20 pg/mL), aprotinin (0.24 pg/mL), or soybean trypsin inhibitor (8.3 pg/mL). Anti-coagulant activity was tested by APTT using mouse plasma. Increasing the amount of activated purified mouse PC prolonged the coagulation time of mouse plasma from 30 seconds to 15 seconds dose dependently under the condition used (Fig 5) . These results indicated that mouse PC isolated by crossreaction with PCOl was functionally identical to bovine and human PC in principle, although mouse PC was activated slowly by PC activator. PCOl inhibited the prolongation of the clotting, and PC02, which did not bind with mouse PC, had no effect on mouse plasma.
To prove that thrombosis in mice was induced by PCOl antibody, purified antibodies were administered to mice. Mice were divided into three groups and each group was administered PCOl, PC02, or phosphate-buffered saline (PBS) intravenously (Table 2 ). Dose of antibody was determined from the experiments of PCOl hybridoma-injected mice. Three of five mice that received PCOl started bleeding at the eyelid on the day indicated in parentheses, while apparently there were no changes up to day 10 in other groups. These mice were also examined microscopically. In For personal use only. on September 24, 2017. by guest www.bloodjournal.org From all mice treated with PCO1, the observed thrombi were similar to those of the mice that were injected with PCOl hybridoma (Fig 3D) . The thrombi were slightly observed in mice in which bleeding had not yet been detected. The mice that were administered PC02 or PBS showed no symptoms of thrombosis or hemorrhage. Clear contrast between the effects of PCOl and PC02 on mice suggests that this thrombosis is very likely to be induced by the blockage of mouse PC function by PCOl .
DISCUSSION
Hybridoma technology has provided new probes for the research in biology and medicine, and several types of MoAbs already contributed to the characterization of human
In addition, our findings of thrombus induction in mice by anti-human PC MoAb gave another view of MoAb application.
We have shown that PCOl bound mouse PC. Mouse PC was isolated for the first time from mouse plasma, which showed similar activities to bovine and human PC. The structure and molecular size of mouse PC were also similar to those in bovine and human PC. PCOl crossreacted with bovine, rat, and rabbit PC, suggesting that PCOl recognizes the conserved structure in the Gla-domain of PC. Details of other species' PC will be published elsewhere. PCOl neutralized mouse PC activity in vitro. We could not show the decrease of PC activity level in PCO1-treated mice, since mouse PC-PCOl complex was dissociated in citrate plasma. However, it may be reasonable to explain these severe thromboses by the decrease of functional PC in plasma.
Platelet number and APTT of mouse plasma were not affected by the treatment with either PCOl and PC02 (data not shown), suggesting that PCOl directly affected neither pc. [17] [18] [19] [20] platelet activation nor coagulation cascade. Relatively high doses of antibody required for in vivo experiments may be due to the relatively low affinity of PCOl to mouse PC in plasma, which was suggested by a preliminary competition experiment. It is not well-understood whether PC in 'the blood stream forms a complex with calcium ion that can be recognized by PCO1. In this regard, PCO1, a specific reagent to PC, could be a useful probe to understand the behavior of PC in in vivo animal models. In our mouse model, large excess amounts of PCOl may be necessary to keep the hyperthrombotic state for a certain period before coagulation cascade starts. Deficiency of PC alone is not likely to be sufficient to start coagulation cascade, but some other induction(s) may be required. The reason thrombi were observed mainly in the cephalic vein is not known. Because thrombosis is not localized in the cephalic vein in the case of human PC-deficient patients, this localized effect may be specific for mice or may be the result of unidentified interaction of PCOl in mouse, which remains to be solved.
It has been known that the deficiency of PC causes thrombotic disease." Typical clinical features in homozygous PC-deficient patients are reported to be skin necrosis, microthrombi, and DIC.22 It should be noted that PCO1-injected mice, either with hybridoma or antibodies, shared some symptoms with homozygous PC-deficient patients. This mouse disease model will be useful for in vivo PC research for hereditary and acquired PC deficiency. Our study also suggests possible application of functional MoAbs to produce a relevant factor-deficient animal model in general. 
